Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (NCT01996865), a randomized phase 3 study. The primary outcome is Progression Free Survival (PFS).

2. Clinical Question

3. Trial Design

This was a Phase 3 randomized, parallel-group study with no masking. The registry record lists enrollment of 503 and status as completed. The study start is recorded as 2014-04-01, and the primary completion date as 2024-05-11. The trial title identifies participants with relapsed or refractory follicular, marginal zone, or mantle cell lymphoma.

The design compared two maintenance approaches after lenalidomide plus rituximab induction. Arm A is described as lenalidomide plus rituximab followed by lenalidomide; Arm B is described as the same induction followed by rituximab. This sequencing matters for interpretation: the primary comparison is between treatment strategies that share the induction phase and differ in the subsequent maintenance approach. The registry record does not provide enough complete arm-description text to reproduce every treatment schedule, so no further schedule detail is inferred.

The primary endpoint population is identified as all randomized participants in both arms, as prespecified in the protocol. The posted primary endpoint summaries give n=135 for Arm A and n=132 for Arm B. These are the endpoint group counts reported with the results; they should not be substituted for the overall enrollment figure. The reasons for the difference between enrollment and these endpoint counts are not reported in the registry record.

Progression-free survival was defined from the first maintenance dose to the first objective documentation of progression or death from any cause. The endpoint description states that Kaplan-Meier estimates were used and that progression events were determined using a modification of the IWG 1999 criteria. A Cox regression analysis is also reported for the comparison between arms. Details beyond these stated methods, including covariate adjustment and the trial's original sample-size justification, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 503 participants joined this study. All participants started in the induction period; only those who did not progress after 12 cycles of treatment were randomized to receive treatment in the maintenance period.

Induction Period

Reasons for not completing this period:

Maintenance Period

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All randomized participants in Arm A and Arm B, as prespecified in the protocol

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants started in the induction and maintenance periods and are accounted for in this arm.

6. Primary Endpoint

The registry lists the primary outcome as Progression Free Survival (PFS), measured over From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks).

Progression-free survival measures the time from the first dose of maintenance therapy until the first objective documentation of tumor progression or death from any cause, whichever occurs first. It therefore combines disease progression and death into a single time-to-event outcome. The registry record states that progression events were determined using a modification of the IWG 1999 criteria, and that the analysis used Kaplan-Meier estimates.

As a general statistical concept, a time-to-event endpoint uses both the event and the time at which it occurs. Participants whose event has not been observed by the end of their available follow-up can still contribute information up to that point; this is commonly handled through censoring in survival analysis. The precise censoring rules used in this trial are not reported in the registry record.

The median is the time by which the estimated event-free proportion has reached the halfway point. It gives a clinically interpretable summary of the event-time distribution, while the Kaplan-Meier curve can show how that distribution unfolds across follow-up. A Cox-model hazard ratio offers a relative comparison of event rates over follow-up under the model's assumptions. These summaries answer related but different questions, and neither alone describes every feature of the survival experience. The endpoint is used in trials because it captures both whether and when progression or death occurs, but its interpretation depends on the definition of events, follow-up, and analysis methods.

7. Results Posted in the Registry

• Arm A: Lenalidomide + Rituximab vs Arm B: Rituximab: hazard ratio 0.80 (95% CI 0.60–1.20), reported p = 0.330 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Overall Survival (OS)

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Regression, Cox); it was not recalculated.
• Result:
  • Arm A: Lenalidomide + Rituximab vs Arm B: Rituximab: hazard ratio 0.70 (95% CI 0.40–1.10), reported p = 0.122 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between Arm A: Lenalidomide + Rituximab vs Arm B: Rituximab and the control. The interval gives the range of effects that remain compatible with the data.

Improvement of Response (IOR)

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Arm B: Rituximab: 11.4% (15/132) versus 20.0% (27/135) on control; risk difference -8.6 percentage points (95% CI -17.3 to 0.0), risk ratio 0.57 (0.32–1.02); unadjusted two-proportion z-test p = 0.053.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm B: Rituximab and the control. The interval gives the range of effects that remain compatible with the data.

Overall Response Rate (ORR)

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Arm B: Rituximab: 79.0% (83/105) versus 85.2% (98/115) on control; risk difference -6.2 percentage points (95% CI -16.3 to 4.0), risk ratio 0.93 (0.82–1.05); unadjusted two-proportion z-test p = 0.231.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm B: Rituximab and the control. The interval gives the range of effects that remain compatible with the data.

Across the posted secondary outcomes, the point estimates generally lean in the same direction as the primary hazard-ratio estimate: several favor Arm A over Arm B, while their uncertainty does not establish a clear difference. The overall-survival comparison is a time-to-event result, and the response outcomes are based on participant proportions. These endpoints describe different aspects of outcome and should not be treated as interchangeable confirmations of the primary endpoint.

The secondary results add context, but they do not overturn the primary interpretation. The primary progression-free survival comparison has a confidence interval that includes 1 and a reported p-value of 0.330. The secondary comparisons also have uncertainty, and the registry record does not report an overall multiplicity strategy for interpreting them. A consistent direction across several estimates can be suggestive, but it does not by itself establish a reliable treatment effect, especially when outcomes are correlated and multiple comparisons are examined.

Unadjusted secondary results carry less weight as confirmatory evidence because they may not account for the number of outcomes tested, planned covariates, or the full analysis structure. As a general statistical concept, testing many outcomes increases the chance that at least one result appears notable by chance if each is judged separately. Appropriate multiplicity control or a prespecified hierarchy can address that issue, but such procedures are not reported in the registry record. The binary secondary comparisons should therefore be read as descriptive or exploratory unless their confirmatory status and analysis plan are documented elsewhere in the record.

Some secondary outcomes are listed in the registry without posted results in the registry record for this analysis. Their findings and relationship to the primary result are not reported in the registry record. The overall pattern is consequently limited to the secondary results with posted numerical summaries, rather than a complete assessment of every outcome listed for the trial.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Overall Survival (OS)
• Improvement of Response (IOR)
• Overall Response Rate (ORR)
• Complete Response Rate (CRR)
• Duration of Response (DOR)
• Time to Next Anti-lymphoma Treatment
• Time to Histological Transformation
• Duration of Complete Response (DOCR)

9. Statistical Interpretation

10. Statistical Methods Explained

Kaplan-Meier estimation is a method for describing time until an event when participants can have different lengths of follow-up. It uses the observed event times and accounts for participants whose event has not been observed by the end of their available follow-up. In this trial, the stated event was objective disease progression or death from any cause, whichever occurred first. The registry record says that progression events were evaluated using a modification of the IWG 1999 criteria.

What does a median time-to-event estimate mean?

For a time-to-event outcome, the median is the point at which the estimated proportion remaining event-free has reached one half. It is not an arithmetic average of participants' observed follow-up times. The posted median progression-free survival estimates are 263.1 weeks for Arm A and 229.1 weeks for Arm B. The registry record reports lower confidence limits but does not report upper limits for these medians. A median can be difficult to estimate precisely when follow-up is limited or relatively few participants experience the event, but the registry record does not give enough information to identify the reason for the unreported upper limits in this study.

What does the Cox hazard ratio describe?

The Cox regression model compares the hazard of an event between groups over follow-up. In general terms, a hazard is the event rate among participants who have not yet experienced the event, considered at a given point in time. The reported hazard ratio is 0.8 for Arm A versus Arm B. A value below 1 indicates a lower estimated hazard in the numerator group relative to the reference group, while a value of 1 indicates no relative difference in the model's hazard comparison. This is a relative measure; it does not directly state how many weeks an individual participant may gain or how many participants avoid an event.

The usual interpretation of a Cox hazard ratio assumes that the relative hazards are adequately represented by a single ratio over follow-up. This is often called the proportional-hazards assumption. The registry record reports a Cox regression analysis but does not report whether that assumption was assessed, whether the model included covariates, or whether alternative time-to-event analyses were conducted. Consequently, the hazard ratio should be read as the reported model-based summary rather than as a full description of all possible differences in event timing.

How should the p-value be read?

The reported p-value for the primary hazard ratio is 0.330. As a general statistical concept, a p-value describes how incompatible the observed data are with a specified null hypothesis, under the model and analysis assumptions. It is not the probability that the null hypothesis is true, nor does it measure the size or clinical importance of an effect. A p-value that does not cross a conventional threshold does not prove that there is no difference. The registry record does not state the full testing plan or whether other confirmatory tests were prespecified.

The 95% confidence interval for the hazard ratio is 0.6 to 1.2. It includes 1, the value corresponding to no relative hazard difference. The interval also includes values on either side of 1, which is why the point estimate alone should not be treated as a definitive conclusion. Confidence intervals and p-values are related summaries of uncertainty when they arise from compatible models and tests, but they are not interchangeable descriptions.

Why can time-to-event data require special care?

Participants enter follow-up at a defined starting point, here the first dose of maintenance therapy, and may have different amounts of observed time. Some may have an event, while others may be censored because an event was not observed during their recorded follow-up. Survival methods are designed to use the available time without treating every participant as if they had identical follow-up. Their validity depends on appropriate event definitions and censoring assumptions. The registry record does not report the detailed censoring procedures, missing-outcome rules, or event counts needed to evaluate those features fully.

As a general concept, over-dispersion is variation greater than expected under a model that assumes a particular variance structure. It can make standard errors too small if the analysis does not account for it. The primary endpoint is a time-to-event outcome analyzed with Kaplan-Meier and Cox methods, not a count outcome for which a simple over-dispersion assessment is directly described in the registry record. No trial-specific over-dispersion assessment is reported.

Finally, all randomized participants are identified as the prespecified primary population. This is important because analysis populations can affect interpretation if participants are excluded after randomization. The registry record does not detail the handling of protocol deviations, treatment discontinuation, crossover, or missing endpoint assessments. Those methods should not be assumed from the reported endpoint definition alone.

11. Confidence Intervals and Precision

The primary hazard-ratio estimate is 0.8, and its 95% confidence interval is 0.6 to 1.2. The interval crosses 1, so it includes both a lower relative hazard for Arm A and a higher relative hazard for Arm A compared with Arm B. The reported p-value is 0.330. Taken together, the point estimate and interval indicate uncertainty about the direction and size of the relative difference, rather than a precise estimate that excludes no difference.

A confidence interval is a range of estimates compatible with the observed data under the statistical method and its assumptions. In general, a narrower interval indicates greater precision, while a wider interval indicates more uncertainty. It does not mean that there is a 95% probability that the fixed true value lies within this particular interval.

The median progression-free survival estimates are 263.1 weeks in Arm A and 229.1 weeks in Arm B. Their reported lower confidence limits are 166.1 weeks and 173.7 weeks; upper confidence limits are not reported in the registry record. Without both interval limits, precision cannot be assessed from a complete two-sided interval for either median. The arm-specific counts reported with these results are 135 and 132.

Precision also depends on the number and timing of events, the amount of follow-up, and the distribution of censoring. The registry record does not report the primary event count or detailed follow-up distribution by arm. The confidence interval is therefore the most direct posted indication of uncertainty for the hazard-ratio comparison, while the missing upper limits constrain interpretation of the median estimates.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are illustrations based on the observed effect, not the trial's original design justification. The original sample-size assumptions are not reported in the registry record. For the time-to-event outcomes, the figures are total events needed across the groups, not participants per arm. For the other outcomes, they are participants per arm.

The listed planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to be detected is set to the stated fraction of the observed effect. The time-to-event calculations use the Schoenfeld approach. These assumptions make the figures conditional planning examples; changing the target effect or other assumptions would change the required event or participant count.

The 80% power column means the illustrative number of events or participants needed for an 80% chance of detecting the stated effect under the planning assumptions, if that effect were the true effect and the model assumptions held. The 90% power column gives the corresponding requirement for a 90% chance. These are design probabilities for a hypothetical study, not probabilities that the observed result is true. The listed figures are not observed power.

Rows that plan for a smaller fraction of the observed effect require more information because smaller differences are harder to distinguish from random variation. That additional information can come from more participants for binary outcomes or more events for time-to-event outcomes. The planning display should therefore be read by matching the outcome type, target effect fraction, and desired power level, rather than by treating one number as a universal enrollment target. These illustrations do not establish that the completed trial was underpowered or that its own sample-size plan used the same assumptions.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.800, so ln(HR) = -0.2231.
2. d = 4 × (1.96 + 0.842)² / [ln(0.800)]² = 630.5, rounded up to 631 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.8                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(1996865)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 631 (80% power), 845 (90% power)
 75% of observed effect: events = 1,121 (80% power), 1,501 (90% power)
 50% of observed effect: events = 2,523 (80% power), 3,377 (90% power)
Simulated power with 631 events: 0.796 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Group-Sequential Design Analysis

Many time-to-event trials, especially in oncology, stop or report early when interim data are overwhelming, so a single fixed-sample number understates the real design problem. The calculation below is an illustrative group-sequential design built from this trial's posted control median and hazard ratio. The registry record does not state the planned number of looks or the spending function, so the design is a planning illustration, not a reconstruction of the protocol. Assumed: one-sided α = 0.025, 90% power, three equally spaced looks on information, Lan-DeMets O'Brien-Fleming spending, 24 months of accrual, 60 months in total and a 1% monthly dropout hazard.

Under these assumptions the design needs about 2,457 participants in total, with the boundaries below.

Fixed design versus group-sequential alternatives

Group-sequential designs cost a small increase in maximum sample size and events compared with the fixed design, in exchange for the chance to stop early for overwhelming efficacy. O'Brien-Fleming spending keeps early boundaries very conservative and the final boundary close to the fixed-design value, whereas Pocock spending spends more alpha early.

Sensitivity to a smaller true effect

Planning for exactly the observed effect is optimistic, because observed effects in published trials tend to be somewhat larger than the true effect. The table repeats the main design (three looks, O'Brien-Fleming spending, 90% power) for smaller true hazard ratios.

For context, this trial enrolled 503 participants.

Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993. Agreement between the two packages confirms the boundary calculation.

R code and output

suppressWarnings(suppressMessages({ library(gsDesign); library(rpact) }))
med_control <- 52.8692307692308          # control-arm median, months (converted from the posted unit)
hr          <- 0.8          # hazard ratio used for planning
lambdaC     <- log(2) / med_control
eta         <- 0.01               # dropout hazard per month (assumption)
acc_months  <- 24                 # accrual duration (assumption)
study_months<- 60                 # total study duration (assumption)

design <- function(k, sfu, beta, h = hr) gsSurv(k = k, test.type = 1, alpha = 0.025, beta = beta, sfu = sfu,
  lambdaC = lambdaC, hr = h, hr0 = 1, eta = eta, gamma = 1, R = acc_months, T = study_months, minfup = study_months - acc_months)

# Main design: 3 looks, Lan-DeMets O'Brien-Fleming spending, one-sided alpha 0.025, 90% power
x <- design(3, sfLDOF, 0.10)
cat(sprintf("N_TOTAL|%s\n", format(ceiling(sum(x$gamma * x$R)), big.mark = ",")))
for (i in 1:3) cat(sprintf("GS|%d|%.1f|%.0f|%.3f|%.5f|%.5f\n", i, x$T[i], x$n.I[i], x$upper$bound[i], pnorm(-x$upper$bound[i]), cumsum(x$upper$spend)[i]))
cat("\n"); print(gsBoundSummary(x))

# Comparison of designs
cmp <- list(list("Fixed design, one analysis", 1, sfLDOF), list("Two looks, O'Brien-Fleming", 2, sfLDOF),
            list("Three looks, O'Brien-Fleming", 3, sfLDOF), list("Three looks, Pocock", 3, sfLDPocock))
cat("\n")
for (b in c(0.20, 0.10)) for (d in cmp) {
  y <- design(d[[2]], d[[3]], b)
  cat(sprintf("DES|%s|%d|%.0f|%s|%.1f\n", d[[1]], round(100 * (1 - b)), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ","), tail(y$T, 1)))
}

# Sensitivity: what if the true effect is smaller than the observed one? (3 looks, O'Brien-Fleming, 90% power)
cat("\n")
for (fr in c(1, 0.75, 0.5)) {
  y <- design(3, sfLDOF, 0.10, exp(log(hr) * fr))
  cat(sprintf("SENS|%.2f|%.3f|%.0f|%s\n", fr, exp(log(hr) * fr), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ",")))
}

# Independent cross-check of the boundaries with rpact
r <- getDesignGroupSequential(kMax = 3, alpha = 0.025, beta = 0.10, sided = 1, typeOfDesign = "asOF", informationRates = x$timing)
cat(sprintf("\nCross-check, upper boundaries: gsDesign %s | rpact %s\n", paste(round(x$upper$bound, 3), collapse = ", "), paste(round(r$criticalValues, 3), collapse = ", ")))

Method: LachinFoulkes 
    Analysis              Value Efficacy
   IA 1: 33%                  Z   3.7103
     N: 2416        p (1-sided)   0.0001
 Events: 286       ~HR at bound   0.6444
   Month: 24   P(Cross) if HR=1   0.0001
             P(Cross) if HR=0.8   0.0338
   IA 2: 67%                  Z   2.5114
     N: 2458        p (1-sided)   0.0060
 Events: 571       ~HR at bound   0.8103
   Month: 38   P(Cross) if HR=1   0.0060
             P(Cross) if HR=0.8   0.5603
       Final                  Z   1.9930
     N: 2458        p (1-sided)   0.0231
 Events: 856       ~HR at bound   0.8726
   Month: 60   P(Cross) if HR=1   0.0250
             P(Cross) if HR=0.8   0.9000



Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993

15. Analyses Reported by the Sponsor

The registry record reports the primary comparison as a Cox regression hazard ratio of 0.8, with a 95% confidence interval of 0.6 to 1.2 and p=0.330. The posted primary comparison and the sponsor's reported analysis agree; no discrepancy is indicated. For this time-to-event endpoint, the sponsor's model-based analysis is the central inferential result and should take precedence over a simple recalculation from summary information.

The registry record also reports a Cox hazard ratio for overall survival of 0.7, with a 95% confidence interval of 0.4 to 1.1 and p=0.122. The reported-analysis entries are available for the time-to-event comparisons, but no sponsor-reported analysis is listed for the binary secondary outcomes. Any unadjusted comparison calculated from posted counts or percentages is therefore a separate descriptive recalculation, not a substitute for a sponsor model or a prespecified adjusted analysis.

The registry record does not report whether the sponsor's Cox analyses included covariate adjustment, how assumptions were checked, or whether additional sensitivity analyses were conducted. The distinction is important: an analysis recalculated from summary data cannot recover individual participant follow-up times, censoring details, stratification, or model adjustments that may have been used in the sponsor's analysis. No disagreement between sponsor and recalculated results is identified in the registry record.

16. Multiplicity, Missing Data and Analysis Populations

The registry record lists multiple secondary outcomes, including overall survival, improvement of response, overall response rate, complete response rate, duration of response, time to next anti-lymphoma treatment, time to histological transformation, and duration of complete response. The record also lists additional outcome measures beyond those with numerical results discussed in the posted summaries. Testing multiple outcomes creates a multiplicity issue: when each result is considered separately, the chance of at least one apparently notable result can increase. As a general statistical principle, confirmatory interpretation is stronger when the outcome hierarchy and multiplicity adjustment are prespecified and reported.

Multiplicity adjustment, a testing hierarchy, and the distinction between confirmatory and exploratory secondary outcomes are not reported in the registry record. The registry also does not report a complete statistical analysis plan, including the planned handling of all secondary comparisons. The unadjusted secondary results should therefore not be interpreted as if they were independent confirmatory tests.

The primary analysis population is stated as all randomized participants in Arm A and Arm B, as prespecified in the protocol. However, detailed analysis-population definitions for the secondary outcomes are not reported in the registry record. The posted group counts vary across outcomes. Reasons for those differences, including the effects of unavailable assessments or outcome-specific eligibility, are not reported in the registry record.

Missing-data handling is also not described in sufficient detail. The record does not specify how missing response assessments, loss to follow-up, treatment discontinuation, or other unavailable outcome information were handled. For the time-to-event analyses, the starting point and event definition are stated, but detailed censoring rules and sensitivity analyses are not reported. These omissions limit assessment of how incomplete follow-up may affect estimates and whether conclusions are robust to alternative assumptions.

Interim analyses and stopping rules are not reported in the registry record. The original sample-size justification and any prespecified statistical thresholds beyond the reported results are also not reported. Without those details, it is not possible to fully assess the trial's intended error control or distinguish all planned analyses from analyses added after the study began.

17. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: basal cell carcinoma (7.5%), pneumonia (6.0%), squamous cell carcinoma of skin (3.7%), neutropenia (3.0%), febrile neutropenia (2.8%).

The registry record gives serious adverse-event and other adverse-event counts for the induction period and for each maintenance arm. During induction, 172 of 500 participants are listed as affected by a serious adverse event and 491 of 500 as affected by another adverse event; 112 deaths are listed. For Arm A maintenance, the corresponding counts are 57 of 134 for serious adverse events and 129 of 134 for other adverse events, with 26 deaths. For Arm B maintenance, they are 22 of 132 and 106 of 132, with 32 deaths.

The registry also lists the most frequent serious adverse-event terms and their percentages: basal cell carcinoma, 7.5%; pneumonia, 6.0%; squamous cell carcinoma of skin, 3.7%; neutropenia, 3.0%; febrile neutropenia, 2.8%; and atrial fibrillation, 2.2%. These terms describe reported serious events; they do not establish that a treatment caused an event. The registry record does not provide enough detail to determine event overlap, timing, severity grading, exposure-adjusted rates, or attribution. The different periods and group sizes should be kept in mind when reading the counts, and they should not be treated as directly comparable rates without additional analysis.

18. What the Result Does, and Does Not, Mean

The primary result is an estimate of progression-free survival for two maintenance strategies after lenalidomide plus rituximab induction. The posted median estimates are 263.1 weeks for Arm A and 229.1 weeks for Arm B. The Cox hazard ratio is 0.8, with a 95% confidence interval of 0.6 to 1.2 and p=0.330. The interval includes the no-relative-difference value, so the data as posted leave uncertainty about both the direction and magnitude of the relative effect.

This result does not prove that the strategies are identical, nor does it establish that one is superior. A non-significant comparison is not evidence of equivalence. Demonstrating equivalence or non-inferiority requires a design with prespecified margins and appropriate analyses; those details are not reported in the registry record. Similarly, the point estimate alone should not be read as a definitive estimate of benefit.

The comparison applies to the treatment sequence studied: lenalidomide plus rituximab induction followed by one of two different maintenance approaches. It does not answer whether the induction combination is better than another induction regimen, whether maintenance is better than no maintenance, or how the results apply to lymphoma types or clinical settings outside those named in the registry record.

The registry results also do not provide a complete account of the effects that matter to individual participants. The posted outcomes include survival, response, and adverse-event summaries, but missing analysis details and incomplete secondary results limit the scope of conclusions. Results from this trial alone do not establish an individual treatment choice, and they should not be interpreted as medical advice. The central statistical message is a directionally lower estimated hazard for Arm A, accompanied by an interval that remains compatible with no relative difference and with effects in either direction.

19. Why This Trial Matters Statistically

This trial is statistically informative because it compares two maintenance strategies after a shared lenalidomide-plus-rituximab induction in a randomized, parallel-group design. Random allocation supports a causal comparison in principle by balancing measured and unmeasured prognostic factors on average, although the registry record does not report details of allocation concealment or implementation. The open-label design is relevant because treatment knowledge can influence aspects of care, assessment, or reporting, particularly for outcomes involving judgment. The primary endpoint's objective progression criteria may reduce some subjectivity, but the registry record does not describe any masking of outcome assessment.

The trial also illustrates why an effect estimate and its uncertainty should be read together. The primary hazard-ratio estimate is below 1, but its 95% confidence interval crosses 1 and the reported p-value is 0.330. This makes it inappropriate to treat the point estimate as a settled conclusion. The median estimates add a time-based description, while the Cox analysis summarizes relative hazard across follow-up; each contributes a different perspective.

Finally, the trial makes clear that interpretation depends on more than a primary result. Secondary outcomes, adverse-event counts, follow-up, missing-data handling, multiplicity, and analysis populations all shape what can be concluded. Some of these details are not reported in the registry record, so the estimates are best understood with those limits in view. For statisticians and clinical researchers, the case highlights the importance of prespecified analyses, transparent reporting, and explicit uncertainty when communicating results from complex treatment sequences.

20. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific reporting gaps constrain interpretation. The primary endpoint description gives the event definition, Kaplan-Meier method, and modified IWG 1999 criteria, but the registry record does not report the number of primary events by arm, detailed censoring rules, or a full account of follow-up by arm. The reported median confidence limits have lower bounds but no upper bounds, limiting assessment of precision for those medians.

The complete treatment schedules are not available in the arm descriptions recorded here, so the full timing and dosing details cannot be reconstructed. The comparison should therefore be described at the level of common induction and differing maintenance strategies, without inferring unreported schedule elements. The registry record also does not report model covariates, proportional-hazards checks, sensitivity analyses, or detailed handling of treatment discontinuation and protocol deviations.

The posted group counts differ across outcomes, but reasons for those differences are not reported in the registry record. Missing-data methods, analysis populations for secondary outcomes, interim analyses, and stopping rules are also not reported. Multiple secondary outcomes are listed, while a multiplicity strategy and confirmatory hierarchy are not reported. These gaps make secondary findings harder to interpret as a coherent confirmatory set.

Finally, the open-label design may matter for outcomes that depend on clinical judgment or assessment. The registry record does not state whether progression assessments were independently reviewed or masked. The results therefore support interpretation of the reported randomized comparison, but not assumptions about unreported design protections or analysis procedures.

21. Related Tutorials

22. Related Statistical Calculators

23. Sources

• ClinicalTrials.gov: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. — NCT01996865.
• Registry record last updated 2025-07-10; status last verified 2025-07.
• Results first posted 2025-07-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

24. Record Summary

NCT01996865 is a completed Phase 3 randomized, open-label, parallel-group study with enrollment of 503. It compared lenalidomide plus rituximab induction followed by lenalidomide maintenance with the same induction followed by rituximab maintenance in relapsed or refractory follicular, marginal zone, or mantle cell lymphoma.

The primary endpoint was progression-free survival from the first maintenance dose to objective progression or death from any cause. The reported Cox hazard ratio was 0.8, with a 95% confidence interval of 0.6 to 1.2 and p=0.330. The interval includes 1, leaving uncertainty about the relative difference between strategies. The registry record does not report several details needed for fuller assessment, including the primary event count, missing-data procedures, and the trial's original sample-size justification.